Overview

Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the safety and pharmacokinetics of Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System to Cefazolin 1.5g for Injection USP and Dextrose Injection USP in daily doses of 6g in healthy adult subjects for 11 days of administration.
Phase:
Phase 1
Details
Lead Sponsor:
B. Braun Medical Inc.
Collaborator:
Parexel
Treatments:
Cefazolin